Balyasny Asset Management L.P. Invests $4.95 Million in Upstream Bio, Inc. (NASDAQ:UPB)

Balyasny Asset Management L.P. acquired a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 301,152 shares of the company's stock, valued at approximately $4,951,000. Balyasny Asset Management L.P. owned 0.56% of Upstream Bio as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. BNP Paribas Financial Markets bought a new position in shares of Upstream Bio in the fourth quarter worth about $25,000. US Bancorp DE purchased a new position in shares of Upstream Bio during the fourth quarter worth approximately $27,000. Legal & General Group Plc bought a new stake in shares of Upstream Bio during the fourth quarter valued at approximately $28,000. Summit Investment Advisors Inc. purchased a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $30,000. Finally, Tower Research Capital LLC TRC bought a new position in Upstream Bio in the fourth quarter worth approximately $47,000.

Upstream Bio Stock Down 1.2 %

Shares of NASDAQ UPB opened at $8.73 on Friday. Upstream Bio, Inc. has a twelve month low of $5.14 and a twelve month high of $29.46. The business has a fifty day simple moving average of $8.03 and a two-hundred day simple moving average of $13.50.

Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.71 million. As a group, sell-side analysts expect that Upstream Bio, Inc. will post -4.3 EPS for the current year.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.